Professionals 223 Users Online

Europe Urethral Bulking Systems Market

Rising prevalence of urinary incontinence amongst the female population to drive up the sales of urethral bulking systems

Europe Urethral Bulking Systems Market Segmented By Pyrolytic Carbon-coated Graphite Beads, Calcium Hydroxylapatite-based, Polydimethylsiloxane Macroparticle, Polyacrylamide Hydrogel, Hyaluronic Acid-based Product

Europe Urethral Bulking Systems Market Outlook (2023-2033)

Europe revenue from the Europe urethral bulking systems market stands at US$ 23.6 Mn in 2022, with the global market estimated to surge ahead at a CAGR of 6.0% to reach a valuation of US$ 44.6 Mn by the end of 2033.

Attributes Key Insights

Europe urethral bulking systems Market Size (2022)

US$ 23.6 Mn

Projected Market Value (2033)

US$ 44.6 Mn

Europe Market Growth Rate (2023-2033)

6.0% CAGR

Top 3 Countries Share (2022)

50.5%

As assessed by Persistence Market Research, hospitals segment is expected to hold a largest market value of US$ 70.0 Mn by 2023 within the Europe market. Overall, Europe urethral bulking systems market sales account for approximately 2.9% revenue share in the global urinary incontinence market, which was valued at around US$ 777.0 Mn at the end of 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of the Europe Market from 2016 to 2022 Vs Market Outlook for 2023 to 2033

The Europe market for Europe urethral bulking systems recorded a historic CAGR of 5.0% in the last 6 years from 2016 to 2022.

The public is becoming more aware of treatments for urine incontinence. Stress urinary incontinence patients report embarrassment, stress, and discomfort associated with female urine incontinence to be their top concerns, particularly in social settings.

The World Health Organization, several NGOs, and other healthcare groups around the world have raised awareness through a number of efforts, which has enhanced the acceptance of female stress urine incontinence as a problem and the range of treatment options available to women regionally. Over the upcoming years, it is anticipated that these devices will become more widely used.

The only non-particulate urethral bulking agent on the current market now is Bulkamid. Although Bulkamid has been on the market in Europe since 2003, the FDA very recently approved the drug in January 2020. The product is anticipated to increase at a significant rate during the projection period as a result of the effectiveness and promising results.

  • Additionally, the recent FDA approval of Bulkamid is anticipated to have a positive impact on the development and sales of non-particulate urethral bulking agents.

The urethral bulking system players are actively working with distributors to expand their sales reach and boost income generation. These cooperative actions aid the manufacturers in building a larger clientele and a stronger presence in the market.

  • Palette Life Sciences, Inc. announced in June 2020 the expansion of the European distribution network for Deflux® and Solesta® in more than 20 countries through five top distributors and direct sales.

The Europe market is thus likely to show high growth over the coming years at a CAGR of 6.0% and reach a market size of US$ 44.6 Mn by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What Factors Will Drive the Market to Grow Over Forecast Period?

High pregnancy rate and Increase in Government Support”

The most prevalent type of urine incontinence (UI) among pregnant women is stress urinary incontinence, which is also known to have a bad impact on quality of life of women. Incontinence due to stress was reported by 59% of pregnant women and 31% of women after giving birth, according to a National Center for Biotechnology Information study.

The governments of many nations are also concentrating on raising awareness about female stress urine incontinence. Thus, it is anticipated that throughout the forecast period, the sales of urethral bulking systems would be driven by a significant increase in pregnancy rates, which is a key risk factor for stress urine incontinence, and an increase in government funding.

Rise in Geriatric Population Leading to an Increase in the Prevalence of Stress Urinary Incontinence”

One of the main factors contributing to an increase in stress urine incontinence in women is the rapid rise in the number of elderly women.

  • In 2020, more than one fifth (20.6%) of the EU's women population was 65 years of age or older, according to the Statistical Office of the European Union (Eurostat).In addition, the organization's 2019 data showed that women outnumbered men in the EU-27 population at older ages. More than twice as many very old women (85 years of age and older) were reported as very old men.

Increases in the prevalence of stress urine incontinence are linked to ageing. Therefore, it is anticipated that the ageing population would result in a high prevalence of female stress urine incontinence.

Increasing Efforts by Manufacturers to Create Awareness”

Through various efforts and advertisements, a number of companies are actively concentrating on raising awareness of incontinence. They are also attempting to provide instructional programs that would aid healthcare workers and provide better understanding.

Palette Life Sciences introduced useful new online tools in October 2020 for healthcare experts in France, Germany, Italy, and Spain. To help people understand the signs, causes, and risk factors connected to urological problems and how to treat such disorders, the company also launched these online materials in local languages.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Is there Any Impact on the Growth of the Europe Market?

Presence of Alternatives

A patient with stress urinary incontinence may select any of the treatment choices, including surgery, medication, catheterization, nerve stimulation, or device use, depending on the clinical guidelines and convenience of the healthcare staff. Additionally, it is projected that throughout the projection period, internally accessible alternatives like incontinence care products like intermittent self-catheterization for intermittent catheterization and briefs for underwear will restrain the market for urethral bulking systems.

The demand for technologically advanced female stress urinary incontinence treatments is expected to provide challenges for the market for urethral bulking systems as research and development of such alternatives continues to grow.

“Complications Associated with Urethral Bulking Systems”

There have been a few reported delayed but severe side effects of urethral bulking, including suburethral abscess, urethral prolapse, and particle migration.

A study found that patients who received Durasphere also had incidences of urethral prolapse if they had previously undergone pelvic surgery or had their urethra bulked up. There have been cases of Durasphere carbon bead fragments travelling to nearby and far-off lymph nodes. Additionally, one instance of a periurethral abscess following Bulkamid injection in a patient who had previously undergone a vaginal hysterectomy and a transobturator tape operation following a total vaginal mesh repair was reported.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the Germany Market Booming?

“Rising Number of Urethral Incontinence”

Germany is expected to hold around 20.4% market share in the Europe urethral bulking systems market at the end of 2023.

The market in Germany is primarily driven by the rising incidence of urethral incontinence in females. Menopause, hysterectomy, pregnancy, and childbirth are a few of the major underlying health issues that are causing urethral incontinence in women population. Additionally, a changing lifestyle is a key cause of urethral incontinence.

Will the UK Be a Lucrative Market for the Manufacturers?

“Growing Numbers of Female Patients Suffering from Urinary Incontinence”

UK is expected to hold a market share of around 13.8% by the end of 2023 in the regional market.

According to NICE (National Institute for Health and Care Excellence) estimates, 24% of the female population was affected by stress incontinence in the UK. Overactive bladder and urgency urinary incontinence in was in 7% of the female population and mixed urinary incontinence in 20% of the affected population with urinary incontinence. These numbers are expected to increase in the future as well, as a result demand for urethral bulking systems will also increase.

Category-wise Insights

Which Product is Driving Growth of the Europe Market?

“Better Qualities Offered by Pyrolytic Carbon-Coated Graphite Beads Products”

Pyrolytic carbon-coated graphite beads segment is expected to hold highest share of around 56.0% of the Europe urethral bulking systems market by the end of 2023.

Due to their affordability and lack of adverse effects, the product is in high demand. Better biocompatibility, which means that it causes no adverse reactions when implanted into human bodies, thromboresistance, which means that it resists blood clotting, high durability, high wear resistance, and greater strength are additional qualities that have led to a higher adoption of these products in treatments.

Which End User Segment is Expected to Emerge as a Market Leader in the Future?

“Large Patient Pool Seeking Treatment”

Hospitals segment is expected to hold a largest market value of US$ 70.0 Mn by 2023 within the Europe market.

Urinary incontinence cases are on the rise, mostly in older females, which is driving up the need for treatment procedures. Hospitals are experiencing an increase in the frequency of these procedures as well as a huge patient pool, which has elevated them to the top of the segment.

Competition Landscape

Mergers and acquisitions have emerged as one of the primary growth strategies when taking into account the consolation actions in the European market for urethral bulking systems. Leading urethral bulking system manufacturers are expanding their product lines through acquisitions and seeking out to both established and developing markets. To further solidify their market position, key players are concentrating on methods including growth, new product launches and expanding their sales channels, such as internet sales.

Key instances include:

  • In Feb 2021, the UK-based company Contura and its signature drug Bulkamid, a urethral bulking agent used to treat female stress urine incontinence, was acquired by Axonics Modulation Technologies, Inc.
  • In Sep 2020, in order to support in the marketing of Solesta in the U.S., Palette Life Sciences had established a partnership arrangement with EVERSANA.

Europe Urethral Bulking Systems Industry Report Scope

Attribute Details

Forecast Period

2023-2033

Historical Data Available for

2016-2022

Market Analysis

USD Billion for Value

Key Countries Covered

  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Benelux
  • Nordic Countries
  • Rest of Europe

Key Market Segments Covered

  • Product
  • End user
  • Country

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Key Companies’ Profile

  • Boston Scientific Corporation
  • Coloplast Corporation
  • Axonics Modulation Technologies, Inc. (Contura, Inc.)
  • Palette Life Sciences, Inc.
  • Laborie, Inc.

Customization & Pricing

Available upon Request

Key Segments Covered in Europe Urethral Bulking Systems Industry Research

Product:

  • Pyrolytic carbon-coated graphite beads
  • Calcium Hydroxylapatite Based
  • Polydimethylsiloxane macroparticle
  • Polyacrylamide hydrogel
  • Hyaluronic Acid Based

End User:

  • Hospitals
  • Ambulatory Surgical centers
  • Specialty Clinic

Country:

  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Benelux
  • Nordic Countries
  • Rest of Europe

- Companies Covered in This Report -

  • Boston Scientific Corporation
  • Coloplast Corporation
  • Axonics Modulation Technologies, Inc. (Contura, Inc.)
  • Palette Life Sciences, Inc.
  • Laborie, Inc

- Frequently Asked Questions -

Europe market is currently valued at around US$ 23.6 Mn in 2022.

Sales of the market are set to witness growth at a CAGR of 6.0% and be valued at around US$ 44.6 Mn by 2033.

Demand for the market increased at a 5.0% CAGR from 2016 to 2022.

Germany is expected to hold around 20.4% market share in the Europe urethral bulking systems market at the end of 2023.

UK is expected to hold a market share of around 13.8% by the end of 2023 in the regional market.

Pyrolytic carbon-coated graphite beads segment is expected to hold highest share of around 56.0% of the Europe urethral bulking systems market by the end of 2023.

Boston Scientific Corporation, Coloplast Corporation, and Axonics Modulation Technologies, Inc. (Contura, Inc.) are among the top players within this market space.

Growing prevalence of urinary incontinence, rising geriatric female population and increased government support are key trends within the Europe urethral bulking systems market.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate